Circulating Vitamin D Levels and Alzheimer’s Disease: A Mendelian Randomization Study in the IGAP and UK Biobank
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Observational studies strongly supported the association of low levels of circulating 25-hydroxyvitamin D (25OHD) and cognitive impairment or dementia in aging populations. However, randomized controlled trials have not shown clear evidence that vitamin D supplementation could improve cognitive outcomes. In fact, some studies reported the association between vitamin D and cognitive impairment based on individuals aged 60 years and over. However, it is still unclear that whether vitamin D levels are causally associated with Alzheimer’s disease (AD) risk in individuals aged 60 years and over. Here, we performed a Mendelian randomization (MR) study to investigate the causal association between vitamin D levels and AD using a large-scale vitamin D genome-wide association study (GWAS) dataset and two large-scale AD GWAS datasets from the IGAP and UK Biobank with individuals aged 60 years and over. Our results showed that genetically increased 25OHD levels were significantly associated with reduced AD risk in individuals aged 60 years and over. Hence, our findings in combination with previous literature indicate that maintaining adequate vitamin D status in older people especially aged 60 years and over, may contribute to slow down cognitive decline and forestall AD. Long-term randomized controlled trials are required to test whether vitamin D supplementation may prevent AD in older people especially those aged 60 years and may be recommended as preventive agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Verbanck, M., Chen, C.-Y., Neale, B., & Do, R. (2018) · Nature Genetics · doi:10.1038/s41588-018-0099-7 · Cited by 8,591
Dementia prevention, intervention, and care
Livingston, G., Sommerlad, A., Orgeta, V., Costafreda, S. G., Huntley, J., Ames, D., Ballard, C., Banerjee, S., Burns, A., Cohen-Mansfield, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31363-6 · Cited by 6,072
Avoiding bias from weak instruments in Mendelian randomization studies
Burgess, S., Thompson, S. G., & CRP CHD Genetics Collaboration (2011) · International Journal of Epidemiology · doi:10.1093/ije/dyr036 · Cited by 3,952
Ward, L. D., & Kellis, M. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr917 · Cited by 2,229
Calculating statistical power in Mendelian randomization studies.
Brion, M.-J. A., Shakhbazov, K., & Visscher, P. M. (2013) · International Journal of Epidemiology · doi:10.1093/ije/dyt179 · Cited by 1,751
Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., Hager, K., Andreasen, N., Scarpini, E., Liu-Seifert, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705971 · Cited by 1,049 · cited 1×
“Until now, many clinical trials of therapies for 443 AD have failed, especially the double-blind, placebo444 controlled, phase III trial involving patients with mild 445 dementia due to AD [38, 39].”
BackgroundGWAS on family history of Alzheimer’s disease
Marioni, R. E., Harris, S. E., Zhang, Q., McRae, A. F., Hagenaars, S. P., Hill, W. D., Davies, G., Ritchie, C. W., Gale, C. R., Starr, J. M., et al. (2018) · Translational Psychiatry · doi:10.1038/s41398-018-0150-6 · Cited by 564
Modifiable pathways in Alzheimer’s disease: Mendelian randomisation analysis
Larsson, S. C., Traylor, M., Malik, R., Dichgans, M., Burgess, S., & Markus, H. S. (2017) · BMJ · doi:10.1136/bmj.j5375 · Cited by 382
Emdin, C. A., Khera, A. V., Natarajan, P., Klarin, D., Zekavat, S. M., Hsiao, A. J., & Kathiresan, S. (2017) · JAMA · doi:10.1001/jama.2016.21042 · Cited by 378 · cited 2×
“sible to fully rule out pleiotropy present in any MR 425 study [16, 23, 37].”
BackgroundDale, C. E., Fatemifar, G., Palmer, T. M., White, J., Prieto-Merino, D., Zabaneh, D., Engmann, J. E. L., Shah, T., Wong, A., Warren, H. R., et al. (2017) · Circulation · doi:10.1161/circulationaha.116.026560 · Cited by 345 · cited 1×
“cept test to assess the presence of potential pleiotropy 174 [28], and Mendelian randomization pleiotropy resid175 ual sum and outlier (MR-PRESSO) test to identify 176 the horizontal pleiotropic outliers [29].”
Background
Cited by
Liu, H., Hu, Y., Zhang, Y., Zhang, H., Gao, S., Wang, L., Wang, T., Han, Z., Sun, B.-L., & Liu, G. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-00963-3 · Cited by 51
Self-citationWu, Y., Chen, F., Zhang, T., Miao, M., Zhang, M., Zhang, J., & Chang, E. (2025) · Metabolomics · doi:10.1007/s11306-025-02242-2 · Cited by 2
“…leptin, Branched-chain amino acids, cortisol and AD (Gu et al., 2022; He et al., 2020; Li et al., 2023b; Li et al., 2022; Liu et al., 2023; Ou et al., 2022; Pagoni et al., 2022; Wang et al., 2020; Wu et al., 2021; Yin et al., 2023; Yuesong Pan et al., 2020; Zhang et al., 2020; Zhang et al., 2022).”
Metadata
- Authors
- Wang, L., Qiao, Y., Zhang, H., Zhang, Y., Hua, J., Jin, S., & Liu, G.
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2019-12-02
- Volume
- 73
- Issue
- 2
- Pages
- 609-618
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2993258341
- Cited by
- 51
- References
- 15
- FWCI
- 4.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Circulating Vitamin D Levels and Alzheimer’s Disease: A Mendelian Randomization Study in the IGAP and UK Biobank. https://app.cochat.ai/papers/10.3233/jad-190713
- The paper
- Wang, L., Qiao, Y., Zhang, H., Zhang, Y., Hua, J., Jin, S., & Liu, G. (2020). Circulating Vitamin D Levels and Alzheimer’s Disease: A Mendelian Randomization Study in the IGAP and UK Biobank. Journal of Alzheimer’s Disease. https://doi.org/10.3233/jad-190713
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.